DK0921125T3 - 1,3,8-triazaspiro[4.5]decan-4-on-derivater - Google Patents

1,3,8-triazaspiro[4.5]decan-4-on-derivater

Info

Publication number
DK0921125T3
DK0921125T3 DK98122511T DK98122511T DK0921125T3 DK 0921125 T3 DK0921125 T3 DK 0921125T3 DK 98122511 T DK98122511 T DK 98122511T DK 98122511 T DK98122511 T DK 98122511T DK 0921125 T3 DK0921125 T3 DK 0921125T3
Authority
DK
Denmark
Prior art keywords
triazaspiro
decan
derivatives
Prior art date
Application number
DK98122511T
Other languages
Danish (da)
English (en)
Inventor
Geo Adam
Andrea Cesura
Guido Galley
Francois Jenck
Stephan Roever
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK0921125T3 publication Critical patent/DK0921125T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Color Printing (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
DK98122511T 1997-12-05 1998-11-27 1,3,8-triazaspiro[4.5]decan-4-on-derivater DK0921125T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97121427 1997-12-05

Publications (1)

Publication Number Publication Date
DK0921125T3 true DK0921125T3 (da) 2002-05-13

Family

ID=8227753

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98122511T DK0921125T3 (da) 1997-12-05 1998-11-27 1,3,8-triazaspiro[4.5]decan-4-on-derivater

Country Status (29)

Country Link
US (1) US6043366A (es)
JP (1) JP3366868B2 (es)
KR (1) KR19990062800A (es)
CN (1) CN1118467C (es)
AR (1) AR016428A1 (es)
AT (1) ATE212635T1 (es)
AU (1) AU744338B2 (es)
BR (1) BR9805297B1 (es)
CA (1) CA2255171C (es)
CO (1) CO4990965A1 (es)
CZ (1) CZ399698A3 (es)
DE (1) DE69803653T2 (es)
DK (1) DK0921125T3 (es)
ES (1) ES2170446T3 (es)
HR (1) HRP980613A2 (es)
HU (1) HUP9802807A3 (es)
ID (1) ID21413A (es)
IL (1) IL127399A0 (es)
MA (1) MA26573A1 (es)
NO (1) NO312161B1 (es)
NZ (1) NZ333159A (es)
PE (1) PE135299A1 (es)
PL (1) PL330062A1 (es)
PT (1) PT921125E (es)
SG (1) SG71173A1 (es)
TR (1) TR199802520A2 (es)
TW (1) TW408123B (es)
YU (1) YU55198A (es)
ZA (1) ZA9811128B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237047T3 (es) * 1998-10-23 2005-07-16 Pfizer Inc. Compuestos de 1,3,8-triazaespiro(4,5)decanona como agonistas del receptor orl1.
JP3989247B2 (ja) * 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． ノシセプチン受容体親和性を有するトリアゾスピロ化合物
US7192964B2 (en) * 2001-07-23 2007-03-20 Banyu Pharmaceutical Co., Ltd. 4-oxoimidazolidine-2-spiropiperidine derivatives
DK1491212T3 (da) 2002-03-29 2012-10-29 Mitsubishi Tanabe Pharma Corp Middel til behandling af søvnforstyrrelser
AU2003268512A1 (en) * 2002-09-09 2004-03-29 Janssen Pharmaceutica N.V. Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
AU2003299791A1 (en) * 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
NZ544282A (en) * 2003-05-23 2009-07-31 Zealand Pharma As Triaza-spiro compounds as nociceptin analogues and uses thereof
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
MX2007011546A (es) * 2005-03-22 2007-10-19 Hoffmann La Roche Nueva sal y polimorfos del inhibidor de dipeptidil-peptidasa iv.
EP2035420A2 (en) * 2006-06-20 2009-03-18 Wyeth a Corporation of the State of Delaware Kv1.5 potassium channel inhibitors
CN101622254B (zh) * 2006-11-28 2013-05-29 詹森药业有限公司 3-(3-氨基-2-(r)-羟基-丙基)-1-(4-氟-苯基)-8-(8-甲基-萘-1-基甲基)-1,3,8-三氮杂-螺[4.5]癸烷-4-酮的盐
CN101622241B (zh) * 2007-03-01 2013-05-22 田边三菱制药株式会社 苯并咪唑化合物及其医药用途
JP5490677B2 (ja) * 2007-04-09 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不安及び鬱病の処置のためのｏｒｌ−１受容体リガンドとしての１，３，８−三置換−１，３，８−トリアザ−スピロ［４．５］デカン−４−オン誘導体
PA8801401A1 (es) * 2007-10-25 2009-05-15 Janssen Pharmaceutica Nv Arilindenopirimidinas y su uso como adenosina a2a
TW201016675A (en) * 2008-09-16 2010-05-01 Mitsubishi Tanabe Pharma Corp Crystalline benzoimidazole compound and salt thereof
US20100076003A1 (en) * 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators
WO2010037081A1 (en) * 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
EP2443124B1 (en) 2009-06-16 2014-01-22 Merck Sharp & Dohme Corp. Substituted -1,3,8-triazaspiro[4.5]decane-2,4-diones
JP7002335B2 (ja) * 2015-07-03 2022-01-20 エフ．ホフマン－ラ ロシュ アーゲー Ｄｄｒ１阻害剤としてのトリアザ－スピロデカノン

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161644A (en) * 1962-06-22 1964-12-15 Res Lab Dr C Janssen N V 1-benzyl-4-substituted piperidines
US3155669A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
US3155670A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3238216A (en) * 1963-06-20 1966-03-01 Res Lab Dr C Janssen N V Substituted 1, 3, 8-triaza-spiro (4, 5) decanes
GB1486546A (en) * 1975-02-28 1977-09-21 Yoshitomo Pharma Ind Ltd 4,4-diphenyl-cyclohexylpiperidine compounds and analogues thereof
JPS51100084A (es) * 1975-02-28 1976-09-03 Yoshitomi Pharmaceutical
JPS5212171A (en) * 1975-07-17 1977-01-29 Yoshitomi Pharmaceut Ind Ltd Process for preparation of cyclohexane derivatives
JPS5934713B2 (ja) * 1976-01-05 1984-08-24 ウェルファイド株式会社 脂環式誘導体
US4076821A (en) * 1976-02-27 1978-02-28 Yoshitomi Pharmaceutical Industries, Ltd. 4,4-Diphenylcycloalkylpiperidines and psychotropic compositions thereof
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
GR73633B (es) * 1980-03-10 1984-03-26 Janssen Pharmaceutica Nv
MA19091A1 (fr) * 1980-03-10 1981-10-01 Janssen Pharmaceutica Nv Nouveaux derives de i-(4-aryl-cyclohexyl)piperidine .
EP0114787B1 (de) * 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
JPS6012357B2 (ja) * 1984-01-23 1985-04-01 吉富製薬株式会社 脂環式誘導体
CA2226058C (en) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives

Also Published As

Publication number Publication date
HU9802807D0 (en) 1999-02-01
HUP9802807A3 (en) 2000-01-28
ID21413A (id) 1999-06-10
IL127399A0 (en) 1999-10-28
NZ333159A (en) 2000-06-23
ES2170446T3 (es) 2002-08-01
AR016428A1 (es) 2001-07-04
SG71173A1 (en) 2000-03-21
MA26573A1 (fr) 2004-12-20
NO312161B1 (no) 2002-04-02
DE69803653D1 (de) 2002-03-14
US6043366A (en) 2000-03-28
PT921125E (pt) 2002-06-28
JPH11228575A (ja) 1999-08-24
PE135299A1 (es) 2000-01-18
NO985684D0 (no) 1998-12-04
TW408123B (en) 2000-10-11
CN1118467C (zh) 2003-08-20
HUP9802807A2 (hu) 1999-08-30
CN1222521A (zh) 1999-07-14
YU55198A (sh) 2001-12-26
KR19990062800A (ko) 1999-07-26
AU9608798A (en) 1999-06-24
BR9805297A (pt) 2000-02-01
NO985684L (no) 1999-06-07
CA2255171A1 (en) 1999-06-05
TR199802520A3 (tr) 1999-06-21
ATE212635T1 (de) 2002-02-15
CO4990965A1 (es) 2000-12-26
ZA9811128B (en) 1999-06-07
AU744338B2 (en) 2002-02-21
PL330062A1 (en) 1999-06-07
DE69803653T2 (de) 2002-08-29
JP3366868B2 (ja) 2003-01-14
CA2255171C (en) 2009-09-29
BR9805297B1 (pt) 2010-07-13
HRP980613A2 (en) 1999-08-31
CZ399698A3 (cs) 1999-06-16
TR199802520A2 (xx) 1999-06-21

Similar Documents

Publication Publication Date Title
DE69800896D1 (de) 8-substituierte-1,3,8-Triazaspiro[4,5]decan-4-onderivate
ZA979593B (en) Naphthyridine derivatives.
SI0921125T1 (en) 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
ZA987037B (en) Benzylidene-1-3-dihydro-indol-2-one derivatives having anti-cancer activity.
DE69804273D1 (de) 5h-Thiazolo[3,2-a]pyrimidinderivate
DK0921125T3 (da) 1,3,8-triazaspiro[4.5]decan-4-on-derivater
DK0922050T3 (da) 3-Descladinose-2,3-anhydroerythromycin-derivater
TR199901381A3 (tr) Diaza-spiro[3,5]nonan türevleri.
ZA982969B (en) 1,2,3,4-tetrahydro-benzofuro[3,2-c]pyridine derivatives.
ZA982436B (en) Thiazolimine derivatives.
DE69905798D1 (de) Di- oder Triazaspiro[4,5]decanderivate
HUP0003692A3 (en) Pyrimido[4,5-b]indolyl-alkanecarboxamide derivatives
ZA981307B (en) 4-aminoethoxyindazole derivatives.
ZA985938B (en) Epothilone derivatives.
NO952426D0 (no) Nytt legemiddel som inneholder 3,7-diazabisyklo[3,3,1Ånonan forbindelser
ZA985559B (en) Tetrahydroimidazo Ä2,1-aÜsoquinoline derivatives
ZA966559B (en) Imidazopyridine derivatives.
ZA966323B (en) Camptothecin derivatives.